The microbial metabolite desaminotyrosine protects against graft-versus-host disease via mTORC1 and STING-dependent intestinal regeneration.
Saved in:
| Title: | The microbial metabolite desaminotyrosine protects against graft-versus-host disease via mTORC1 and STING-dependent intestinal regeneration. |
|---|---|
| Authors: | Göttert S; Department of Internal Medicine III, Hematology & Internal Oncology, University Hospital Regensburg, Regensburg, Germany.; Leibniz Institute for Immunotherapy (LIT), Regensburg, Germany., Thiele Orberg E; Department of Internal Medicine III, Hematology & Internal Oncology, University Hospital Regensburg, Regensburg, Germany. erik.orberg@ukr.de., Fan K; Department of Internal Medicine III, Hematology & Internal Oncology, University Hospital Regensburg, Regensburg, Germany.; Leibniz Institute for Immunotherapy (LIT), Regensburg, Germany., Heinrich P; Department of Internal Medicine III, Hematology & Internal Oncology, University Hospital Regensburg, Regensburg, Germany.; Leibniz Institute for Immunotherapy (LIT), Regensburg, Germany., Matthe DM; Department of Medicine 1, Kussmaul Campus for Medical Research, University Hospital Erlangen, University of Erlangen-Nuremberg, Erlangen, Germany.; Deutsches Zentrum Immuntherapie (DZI), University Hospital Erlangen, Erlangen, Germany., Khalid O; Department of Internal Medicine III, Hematology & Internal Oncology, University Hospital Regensburg, Regensburg, Germany.; Leibniz Institute for Immunotherapy (LIT), Regensburg, Germany., Klostermeier L; Department of Internal Medicine III, Hematology & Internal Oncology, University Hospital Regensburg, Regensburg, Germany., Suriano C; Department of Internal Medicine III, Hematology & Internal Oncology, University Hospital Regensburg, Regensburg, Germany.; Leibniz Institute for Immunotherapy (LIT), Regensburg, Germany., Strieder N; Leibniz Institute for Immunotherapy (LIT), Regensburg, Germany., Gebhard C; Leibniz Institute for Immunotherapy (LIT), Regensburg, Germany., Vonbrunn E; Department of Nephropathology, Institute of Pathology, Universitätsklinikum Erlangenm, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany., Mamilos A; Institut of Pathology, University of Regensburg, Regensburg, Germany.; Department of Pathology, German Oncology Center, Limassol, Cyprus., Hirsch D; Institut of Pathology, University of Regensburg, Regensburg, Germany., Meedt E; Department of Internal Medicine III, Hematology & Internal Oncology, University Hospital Regensburg, Regensburg, Germany., Kleigrewe K; Bavarian Center for Biomolecular Mass Spectrometry (BayBioMS), Technical University of Munich, Freising, Germany., Hiergeist A; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany., Schwarz A; Department of Internal Medicine III, School of Medicine and Health, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany., Gläsner J; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany., Ghimire S; Department of Internal Medicine III, Hematology & Internal Oncology, University Hospital Regensburg, Regensburg, Germany., Joachim L; Department of Internal Medicine III, Hematology & Internal Oncology, University Hospital Regensburg, Regensburg, Germany., Voll F; Department of Internal Medicine III, Hematology & Internal Oncology, University Hospital Regensburg, Regensburg, Germany., Neuhaus K; ZIEL - Institute for Food & Health-, Technische Universität München, Freising, Germany., Janssen KP; Department of Surgery, TUM School of Medicine and Health, Klinikum rechts der Isar, Technische Universität München, Munich, Germany., Perl M; Department of Internal Medicine III, Hematology & Internal Oncology, University Hospital Regensburg, Regensburg, Germany., Pielmeier F; Department of Internal Medicine III, Hematology & Internal Oncology, University Hospital Regensburg, Regensburg, Germany.; Leibniz Institute for Immunotherapy (LIT), Regensburg, Germany., Ruland J; German Cancer Consortium (DKTK), partner-site Munich, a partnership between DKFZ and Klinikum rechts der Isar, Munich, Germany.; Center for Translational Cancer Research (TranslaTUM), School of Medicine and Health, Technical University of Munich, Munich, Germany.; Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine and Health, Technical University of Munich, Munich, Germany., Kreutz M; Department of Internal Medicine III, Hematology & Internal Oncology, University Hospital Regensburg, Regensburg, Germany., Weber D; Institut of Pathology, University of Regensburg, Regensburg, Germany., Schmidl C; Leibniz Institute for Immunotherapy (LIT), Regensburg, Germany., Köhler N; Department of Internal Medicine I, Hematology, Oncology, and Stem Cell Transplantation, Faculty of Medicine, Medical Centre, University of Freiburg, Freiburg, Germany.; Centre for Integrative Biological Signalling Studies (CIBSS), University of Freiburg, Freiburg, Germany., Tschurtschenthaler M; Center for Translational Cancer Research (TranslaTUM), School of Medicine and Health, Technical University of Munich, Munich, Germany.; Division of Translational Cancer Research, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.; Chair of Translational Cancer Research and Institute of Experimental Cancer Therapy, TUM School of Medicine and Health, Klinikum rechts der Isar at Technical University of Munich, Munich, Germany., Hoffmann P; Department of Internal Medicine III, Hematology & Internal Oncology, University Hospital Regensburg, Regensburg, Germany.; Leibniz Institute for Immunotherapy (LIT), Regensburg, Germany., Edinger M; Department of Internal Medicine III, Hematology & Internal Oncology, University Hospital Regensburg, Regensburg, Germany.; Leibniz Institute for Immunotherapy (LIT), Regensburg, Germany., Wolff D; Department of Internal Medicine III, Hematology & Internal Oncology, University Hospital Regensburg, Regensburg, Germany., Bassermann F; Department of Internal Medicine III, School of Medicine and Health, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany.; German Cancer Consortium (DKTK), partner-site Munich, a partnership between DKFZ and Klinikum rechts der Isar, Munich, Germany.; Center for Translational Cancer Research (TranslaTUM), School of Medicine and Health, Technical University of Munich, Munich, Germany.; Bavarian Cancer Research Center (BZKF), Munich, Germany., Rehli M; Department of Internal Medicine III, Hematology & Internal Oncology, University Hospital Regensburg, Regensburg, Germany.; Leibniz Institute for Immunotherapy (LIT), Regensburg, Germany., Haller D; ZIEL - Institute for Food & Health-, Technische Universität München, Freising, Germany.; Chair of Nutrition and Immunology, Technische Universität München, Freising, Germany., Evert M; Institut of Pathology, University of Regensburg, Regensburg, Germany., Hildner K; Department of Medicine 1, Kussmaul Campus for Medical Research, University Hospital Erlangen, University of Erlangen-Nuremberg, Erlangen, Germany.; Deutsches Zentrum Immuntherapie (DZI), University Hospital Erlangen, Erlangen, Germany., Büttner-Herold M; Department of Nephropathology, Institute of Pathology, Universitätsklinikum Erlangenm, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany., Herr W; Department of Internal Medicine III, Hematology & Internal Oncology, University Hospital Regensburg, Regensburg, Germany., Gessner A; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany., Heidegger S; Department of Internal Medicine III, School of Medicine and Health, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany.; Center for Translational Cancer Research (TranslaTUM), School of Medicine and Health, Technical University of Munich, Munich, Germany., Holler E; Department of Internal Medicine III, Hematology & Internal Oncology, University Hospital Regensburg, Regensburg, Germany., Poeck H; Department of Internal Medicine III, Hematology & Internal Oncology, University Hospital Regensburg, Regensburg, Germany. hendrik.poeck@ukr.de.; Leibniz Institute for Immunotherapy (LIT), Regensburg, Germany. hendrik.poeck@ukr.de.; Bavarian Cancer Research Center (BZKF), Munich, Germany. hendrik.poeck@ukr.de. |
| Source: | Nature communications [Nat Commun] 2025 Oct 20; Vol. 16 (1), pp. 9282. Date of Electronic Publication: 2025 Oct 20. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-025-65180-6 |
